Myelodysplastic Syndromes: all 2,165 studies
Page 2 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal HematopoiesisRecruitingNCT06691217Phase 2
- ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesRecruitingNCT06656494Phase 1
- A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)RecruitingNCT06616636Phase 1
- Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDSRecruitingNCT06614595
- Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M StratificationRecruitingNCT06612944Phase 2
- TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.Not yet recruitingNCT06602323Phase 2
- Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid LeukemiaRecruitingNCT06599762Phase 2
- TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaNot yet recruitingNCT06598969Phase 2
- A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesNot yet recruitingNCT06594965Phase 2
- HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AMLRecruitingNCT06594445Phase 1
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)RecruitingNCT06577441Phase 2
- Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow CytometryRecruitingNCT06569095
- A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.RecruitingNCT06566742Phase 2
- Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCTRecruitingNCT06551584Phase 1
- A Clinical Trial of TQB3455 Tablets in Patients With Hematological MalignanciesRecruitingNCT06550713Phase 1
- A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)RecruitingNCT06548230Phase 1/2
- Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantRecruitingNCT06543381Phase 1
- VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDSRecruitingNCT06536959Phase 2
- Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenRecruitingNCT06532084Phase 2
- Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06529731Phase 2
- Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide TherapyRecruitingNCT06510868
- Vitamin A and D Supplementation in Allogeneic HCTRecruitingNCT06508099Phase 2
- Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic SyndromeRecruitingNCT06502145Phase 1
- A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic SyndromeRecruitingNCT06501196Phase 1
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsRecruitingNCT06499285Phase 3
- Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell TransplantRecruitingNCT06498973Phase 1
- HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable
- Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromesRecruitingNCT06484062Phase 1
- BeFluBu vs FluBuRux Conditioning in Haploidentical HCTRecruitingNCT06477549Phase 2
- VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDSRecruitingNCT06471946Phase 1/2
- Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 MutationRecruitingNCT06465953Phase 3
- A Study to Evaluate the MNV-201 in Patients With Low Risk MDSRecruitingNCT06465160Phase 1
- ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AMLNot yet recruitingNCT06463327Phase 1
- Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)RecruitingNCT06462365Phase 1
- Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive ChemotherapyRecruitingNCT06439199
- Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaRecruitingNCT06399640Phase 1
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)RecruitingNCT06379945
- A Study of GLB-001 in Patients With Myeloid MalignanciesRecruitingNCT06378437Phase 1
- Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) TrialRecruitingNCT06355583Phase 2
- A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AMLRecruitingNCT06329999Not applicable
- Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell TransplantRecruitingNCT06315309Phase 2
- A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic SyndromeRecruitingNCT06304103Phase 2
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingNCT06303193Phase 1/2
- PTCy and ATG for MSD and MUD TransplantsRecruitingNCT06299462Phase 1/2
- Study of REM-422 in Patients With AML or Higher Risk MDSRecruitingNCT06297941Phase 1
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingNCT06287944Phase 1
- Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin InhibitorsNot yet recruitingNCT06279494Phase 1/2
- A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M ScoreNot yet recruitingNCT06279338Not applicable
- OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot StudyRecruitingNCT06270771
- Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell TransplantRecruitingNCT06265584Phase 2
- Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDSRecruitingNCT06247917Phase 2
- Upfront Related Donor Transplantation in Patients With Myelodisplatic Syndrome : a Phase 2 TrialNot yet recruitingNCT06235398Phase 2
- A Study of TQB3454 Tablets in Patients With Blood TumorsRecruitingNCT06218771Phase 1/2
- TGRX-814 Chinese Phase I/II in Patients With Hematological MalignanciesRecruitingNCT06206174Phase 1/2
- A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS PatientsRecruitingNCT06199557Phase 1/2
- A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic SyndromesRecruitingNCT06196203Phase 2
- Role of BMP Pathway in MDS ProgressionNot yet recruitingNCT06175923
- A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic SyndromesRecruitingNCT06146257Phase 1
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
- Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCTRecruitingNCT06130579Phase 2
- Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeRecruitingNCT06128070Phase 2
- Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary InvolvementRecruitingNCT06111612
- Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDSRecruitingNCT06109064Phase 2
- A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemiaRecruitingNCT06073860
- Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative NeoplasmsRecruitingNCT06063486Phase 2
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
- Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDSNot yet recruitingNCT06050941Phase 2
- UAB 2419-CD34 Selection Using the Automated CliniMACS ProdigyRecruitingNCT06047886Phase 1
- Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDSRecruitingNCT06046313Phase 2
- Study of VIP943 in Subjects With Advanced CD123+ Hematologic MalignanciesRecruitingNCT06034275Phase 1
- Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.RecruitingNCT06022016Not applicable
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesRecruitingNCT06013423Phase 2
- Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination TherapyRecruitingNCT06008405Phase 1
- Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RSNot yet recruitingNCT06006949Phase 4
- Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RSNot yet recruitingNCT06004765Phase 4
- Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid MalignanciesRecruitingNCT05991908Phase 3
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLRecruitingNCT05986240Phase 1
- Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline MutationRecruitingNCT05983991Not applicable
- Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMMLRecruitingNCT05970822Phase 1
- At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced CancerRecruitingNCT05969860Phase 2
- Clonal Hematopoiesis of Immunological SignificanceNot yet recruitingNCT05969821
- Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune NeutropeniaRecruitingNCT05931718
- The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic SyndromesRecruitingNCT05925504Phase 2
- Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TDRecruitingNCT05924100Phase 2
- Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS)RecruitingNCT05924074Not applicable
- Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic SyndromeRecruitingNCT05902416
- A Telehealth Advance Care Planning InterventionRecruitingNCT05875805Not applicable
- Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCTRecruitingNCT05823714Phase 2
- Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAMLRecruitingNCT05807932Phase 1/2
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant DiseasesRecruitingNCT05800210Phase 2
- A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDSRecruitingNCT05788679Phase 2
- Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareRecruitingNCT05745285Not applicable
- Early Detection and Screening of Hematological Malignancies - SANGUINERecruitingNCT05735704
- A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic SyndromesRecruitingNCT05732103Phase 1/2
- A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic SyndromesRecruitingNCT05693909Phase 2
- Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic SyndromeEnrolling by invitationNCT05674539Phase 3
- A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLRecruitingNCT05641259Phase 1
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingNCT05636514Phase 1